home / stock / chsyf / chsyf short
Short Information | China Medical Sys Hldgs (OTCMKTS:CHSYF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 40,181 |
Total Actual Volume | 43,530 |
Short Trends | |
---|---|
Cover Days | 1 |
Short Days | 17 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 2,009 |
Average Short Percentage | 84.01% |
Is there a CHSYF Short Squeeze or Breakout about to happen?
See the CHSYF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-30-2024 | $0 | $0.9313 | $0 | $0 | 10 | 10 | 100% |
11-01-2022 | $1.28 | $1.28 | $1.28 | $1.28 | 667 | 667 | 100% |
04-18-2022 | $1.55 | $1.59 | $1.59 | $1.55 | 2,648 | 1,324 | 50% |
03-24-2022 | $1.62 | $1.62 | $1.62 | $1.62 | 180 | 180 | 100% |
12-29-2021 | $1.7 | $1.7 | $1.7 | $1.7 | 500 | 500 | 100% |
04-06-2021 | $2.2 | $2.2 | $2.2 | $2.2 | 3,800 | 3,800 | 100% |
12-14-2020 | $1.08 | $1.08 | $1.08 | $1.08 | 100 | 100 | 100% |
08-28-2020 | $1.14 | $1.14 | $1.14 | $1.14 | 800 | 800 | 100% |
08-27-2020 | $1.2 | $1.2 | $1.2 | $1.2 | 500 | 500 | 100% |
10-23-2019 | $1.33 | $1.33 | $1.33 | $1.33 | 775 | 750 | 96.77% |
10-22-2019 | $1.34 | $1.33 | $1.34 | $1.33 | 21,500 | 21,500 | 100% |
08-07-2019 | $N/A | $0.97 | $N/A | $N/A | 50 | 50 | 100% |
03-15-2019 | $1.00 | $1.00 | $1.00 | $1.00 | 1,000 | 1,000 | 100% |
02-21-2019 | $1.01 | $0.97 | $1.01 | $0.97 | 3,000 | 1,000 | 33.33% |
02-19-2019 | $1.01 | $1.01 | $1.01 | $1.01 | 3,000 | 3,000 | 100% |
02-04-2019 | $1.02 | $1.02 | $1.02 | $1.02 | 1,000 | 1,000 | 100% |
01-31-2019 | $1.06 | $1.06 | $1.06 | $1.06 | 1,000 | 1,000 | 100% |
01-28-2019 | $0.95 | $0.95 | $0.95 | $0.95 | 3,000 | 3,000 | 100% |
News, Short Squeeze, Breakout and More Instantly...
China Medical Sys Hldgs Company Name:
CHSYF Stock Symbol:
OTCMKTS Market:
SHENZHEN, CHINA, April 23, 2024 (GLOBE NEWSWIRE) -- Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unme...
Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria HONG KONG, China and WILMINGTON, De...
SHENZHEN, CHINA, March 27, 2024 (GLOBE NEWSWIRE) -- On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results. The Company recorded a turnover of RMB8,013 million, a year-on-year decrease of 12.4%; in the case that all medicines ...